EFM
VERV

E Fund Management’s Verve Therapeutics VERV Stock Holding History

E Fund Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,522
Closed -$48.1K – 428
2025
Q1 		$48.1K Buy
+10,522
New +$70.5K ﹤0.01% 394
2024
Q4 		– Sell
-13,554
Closed -$65.6K – 413
2024
Q3 		$65.6K Buy
+13,554
New +$78.7K ﹤0.01% 347
2024
Q2 		– Sell
-20,394
Closed -$271K – 380
2024
Q1 		$271K Buy
20,394
+4,016
+25% +$53.3K 0.02% 291
2023
Q4 		$228K Buy
16,378
+1,981
+14% +$24.6K 0.01% 264
2023
Q3 		$191K Buy
14,397
+1,499
+12% +$24.1K 0.01% 263
2023
Q2 		$242K Sell
12,898
-2,038
-14% -$33.9K 0.02% 254
2023
Q1 		$215K Sell
14,936
-4,587
-23% -$89.8K 0.02% 286
2022
Q4 		$378K Buy
19,523
+7,231
+59% +$192K 0.03% 193
2022
Q3 		$422K Buy
+12,292
New +$392K 0.04% 169
2022
Q2 		– Sell
-9,282
Closed -$212K – 350
2022
Q1 		$212K Buy
+9,282
New +$265K 0.01% 283

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

E Fund Management's VERV Position: Q2 2025 in Review

E Fund Management sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 10,522 shares — an estimated $48.1K sold.

E Fund Management first reported a position in VERV in Q1 2022 and held it in 10 quarters. The position peaked at $422K in Q3 2022. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • E Fund Management reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • E Fund Management sold 10,522 Verve Therapeutics shares in Q2 2025, an estimated $48.1K.
  • E Fund Management first reported a position in Verve Therapeutics in Q1 2022 and held it in 10 quarters.
  • E Fund Management's Verve Therapeutics position peaked at $422K in Q3 2022.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on E Fund Management's 13F filing for Q2 2025, filed 15 Aug 2025.